MGC Pharmaceuticals Ltd.
PDMR Notification
18 July 2023
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') announces, further to the Company's "£0.7 million Fundraising" announcement on 14 July 2023, details of the participation of Persons Discharging Managerial Responsibilities ("PDMRs") in the Subscription in accordance with the UK Market Abuse regulations.
Full details of the shares subscribed by the PDMRs in the Subscription are contained in the disclosure tables below.
Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to them in the Company's announcement made on 14 July 2023.
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Amir Polak | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Chief Pharmaceutical Development Officer | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Shares issued following participation in fundraise | |||
| (d) | Currency | Price | Volume | Total | |
| | GBP | £0.0012 | 4,416,667 | £5,300 | |
| | Aggregated information | ||||
| | GBP | £0.0012 | 4,416,667 | £5,300 | |
| (e) | Date of transaction
| 14 July 2023 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Itay Nissim | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Chief Manufacturing and Supply Chain Officer | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Shares issued following participation in fundraise | |||
| (d) | Currency | Price | Volume | Total | |
| | GBP | £0.0012 | 3,833,333 | £4,600 | |
| | Aggregated information | ||||
| | GBP | £0.0012 | 3,833,333 | £4,600 | |
| (e) | Date of transaction
| 14 July 2023 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Yair Tal | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Chief Information Security Officer | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Shares issued following participation in fundraise | |||
| (d) | Currency | Price | Volume | Total | |
| | GBP | £0.0012 | 2,166,667 | £2,600 | |
| | Aggregated information | ||||
| | GBP | £0.0012 | 2,166,667 | £2,600 | |
| (e) | Date of transaction
| 14 July 2023 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Yifat Steuer | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Chief Operating Officer and Deputy CEO | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Shares issued following participation in fundraise | |||
| (d) | Currency | Price | Volume | Total | |
| | GBP | £0.0012 | 5,833,333 | £7,000 | |
| | Aggregated information | ||||
| | GBP | £0.0012 | 5,833,333 | £7,000 | |
| (e) | Date of transaction
| 14 July 2023 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
--Ends--
Authorised for release by the Managing Director, for further information please contact:
| MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 | MGC Pharmaceuticals Ltd Arron Canicais / Rowan Harland Joint Company Secretaries +61 8 6382 3390 |
| UK Brokers Peterhouse Capital Charles Goodfellow / Lucy Williams / Duncan Vasey +44 207 469 0930 | UK Brokers Oberon Capital Adam Pollock / Aimee McCusker +44 203 179 5300 adampollock@oberoninvestments.com |
| UK IR/PR Advisers IDC Advisory Graham Herring / Tim Metcalfe / Zach Cohen | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.